PhytoMedical Technologies - About PhytomMedical

Click here for Press Release Archive
04/15/2010	PhytoMedical Signs a Letter of Intent (LOI) with a Leading Chinese Research Services Organization to Advance Brain Cancer Drug Candidate PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), a developer of 'D11B', an anti-cancer compound shown in early studies to inhibit the growth of difficult-to-treat brain cancer, today announced that the Company has entered into a Letter of Intent (LOI) with Shanghai Medicilon, Inc.
03/22/2010	PhytoMedical Announces the Appointment of Dr. James F. Lynch as President and CEO PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that Dr. James F. Lynch, formerly a member of the Company's Scientific Advisory Board, has been appointed President and Chief Executive Officer of PhytoMedical, effective March 15, 2010. Mr. Greg Wujek, PhytoMedical's outgoing President and CEO, continues to serve as Director on the Company's Board.
10/14/2009	Click here to view PhytoMedical's Proxy material for the 2009 Annual Meeting of Stockholders
08/05/2009	PhytoMedical Partners with Renowned Specialty Laboratory to Develop an IV Formulation For Its Successfully Tested Anti-Cancer Compound for Glioblastoma PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced their partnership with LATITUDE Pharmaceuticals, Inc. to develop an IV Formulation for its lead anti cancer compound for glioblastoma. LATITUDE Pharmaceuticals, Inc. is a widely recognized expert in the area of drug formulations and delivery systems. “Given LATITUDE’s successful track record in formulation development, we are extremely pleased to have partnered with such an innovative group of experts,” commented PhytoMedical, President, CEO, Greg Wujek. “The development and subsequent testing of the IV Formulation are key components in PhytoMedical’s quest to provide physicians and their patients with an effective treatment option for this most difficult to treat and often deadly form of brain cancer.”
07/01/2009	Letter from the President Q309 It has been a time of historical proportions that has changed the markets and industries forever, including both the pharmaceutical and biotechnology sectors. In the midst of all of this activity PhytoMedical continues to persevere with the successful execution of their business strategy. It is from here that I wanted to take this opportunity to provide you with an update on PhytoMedical’s progress these past months. Therefore, I have taken the liberty of re-circulating our press releases from October 2008 to our most recent in order to provide you with a snapshot of our developmental progress
06/16/2009 Business Wire	PhytoMedical's Anti-Cancer Compound Development Advancing After a Series of Highly Favorable Test Results PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced the advancement of their anti-cancer compound research and development. The culmination of a series of favorable test results conducted over several months have allowed the company to justifiably expand their cancer research efforts which includes the designing of an IV formulation of their key compound.
02/26/2009 Business Wire	A Senior Cancer Researcher Joins PhytoMedical on Heels of Company’s Successful Preclinical Study on Human Brain Cancer. PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced the appointment of Li-Xi Yang, MD, PhD, an experienced scientist on the development of anti-cancer compounds, to the Company's Advisory Board.
02/03/2009 Business Wire	PhytoMedical's Patented Anti-Cancer Compound Eradicates Tumor in Successful In-Vivo Tests Against Human Brain Cancer PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced favorable results from recent in vivo efficacy and toxicity tests where the Company's patented anti-cancer compound was administered to specimens with difficult-to-treat human brain cancer (SF295 glioblastoma xenografts) and, according to researchers, proved to be least toxic and extremely effective in controlling the growth of SF295 human glioblastoma xenografts.
10/27/2008 Business Wire	PhytoMedical's In Vivo Toxicity and Efficacy Tests on Human Colon Cancer Deliver Promising Results PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced the results of it's anti-cancer compound in vivo toxicity and efficacy tests on HCT116 human colon cancer cells was successful. "I am encouraged by the results of our human colon cancer toxicity and efficacy tests which is allowing us to continue to climb our developmental ladder," stated Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc. "We have made some significant progress this past year and look forward to moving to the next phase in our developmental pathway."
10/06/2008 Business Wire	PhytoMedical Renews Sponsored Research Agreement with Dartmouth College PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that it is renewing its Sponsored Research Agreement with Dartmouth College. "I am extremely pleased to have extended our agreement with Dartmouth College," stated Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc. " This past year, Dr. Gordon Gribble and his staff have worked very hard to assure all of our developmental goals were accomplished on time allowing us to move from the initial human cancer cell line in vitro testing to our current development phase seamlessly". Dartmouth Technology Transfer Office Assistant Director, Glennis Gold affirmed, "Our collaboration with PhytoMedical is an excellent example of how technology arising out of academia may be transferred to the private sector in order to serve the public good."
08/11/2008 Business Wire	PhytoMedical Acquires Worldwide License Rights to Patented Novel Anti-Cancer Compounds from Dartmouth College PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that it has entered into an exclusive worldwide license agreement with Dartmouth College to develop, market and distribute new anti-tumor bis-acridines, bis-ellipticines and bis-carbazoles known as intercalating agents developed by leading researcher, Dr. Gordon Gribble, of Dartmouth College.
04/14/2008 Business Wire	PhytoMedical Expands Anti-Cancer Research with Important Efficacy Tests PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that a series of positive outcomes from the Company’s ongoing development of its patented anti-cancer compounds have prompted researchers to now undertake their first-ever efficacy studies, an important advancement in the drug development process.
03/17/2008 Business Wire	PhytoMedical Advances Research of Patented Anti-Cancer Compound with Important Toxicity Tests PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that the Company will initiate the third phase of its drug development program, with researchers undertaking important toxicity studies of several select, patented anti-cancer compounds shown to successfully kill cells associated with several difficult-to-treat human cancers.
03/03/2008 Business Wire	PhytoMedical’s Latest Anti-Cancer Compounds Kill Human Colon Cancer Cells PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced positive results from new tests of the Company’s patented ‘next generation’ anti-cancer compounds, which have demonstrated the ability to kill difficult-to-treat human cancer cells, including colon cancer cells and human glioblastoma cells related to brain cancer, an often fatal form of cancer.
02/04/2008 Business Wire	PhytoMedical Bolsters Cancer Research Following Favorable Results PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that favorable research outcomes from ongoing tests have spurred immediate expansion of the Company’s cancer research program, actively working to develop patented, next-generation anticancer compounds targeting multiple human cancer strains.
01/22/2008 Business Wire	PhytoMedical’s Patented Anti-Cancer Compounds Kill Lung Cancer Cells, a Significant New Finding PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6) today announced that its patented bis-intercalator anti-cancer compound achieved a 50% or greater cancer cell kill rate in new in vitro studies of the DMS 114 strain of human small lung cancer cells, an important outcome given lung cancer’s high mortality rate and the lack of effective treatment options.
01/03/2008 Business Wire	PhytoMedical’s Anti-Cancer Compound Effective at Killing Brain Cancer Cells. PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that research outcomes from ongoing in vitro studies of the Company’s sponsored anti-cancer compounds have successfully demonstrated the ability to kill a strain of human brain cancer cells which is otherwise highly-resistant to currently available drugs.